Henlius (2696.HK) is a global, innovation-driven biopharmaceutical company committed to providing high-quality, affordable biologics to patients worldwide, with a portfolio spanning oncology, autoimmune diseases, ophthalmic diseases, and other therapeutic areas. Since its establishment in 2010, the company has built a fully integrated platform encompassing global research and development, clinical development, regulatory affairs, manufacturing, and commercialization. Henlius has more than 4,000 employees worldwide, with operations and offices in China, the United States, Japan, and other locations. Supported by robust cash flow from its biosimilar business, which is reinvested in innovative R&D, Henlius is steadily advancing into its “Globalization 2.0” phase, continuing to build a replicable and sustainable model for global growth. To date, 10 of the company’s products have received marketing approvals across more than 60 countries and regions, including eight approved in China. Henlius has also achieved several major milestones in the leading biologics markets of the United States and Europe, with four products approved by the U.S. Food and Drug Administration (FDA) and five by the European Commission (EC). These achievements demonstrate that the company’s R&D systems, quality management, and manufacturing capabilities are fully aligned with the highest international standards.